LifeWave Biomedical

Executive Summary

LifeWave Biomedical is a digital health and medical device company focused on transforming heart failure management through its non-invasive, AI-powered CardioConnect™ platform. The platform uses proprietary medical radar technology to measure lung fluid as a direct biomarker for worsening heart failure, enabling early detection and guided therapy optimization from the patient's home. By shifting care from reactive hospitalizations to proactive home monitoring, LifeWave aims to reduce the substantial clinical and economic burden of heart failure, which affects millions worldwide and accounts for billions in healthcare costs annually. The company is based in San Diego and was founded in 2018. LifeWave's approach addresses a critical gap in heart failure care: the lack of continuous, objective monitoring outside clinical settings. Traditional methods rely on weight and symptom tracking, which often detect changes too late. CardioConnect offers a novel, radar-based solution that provides real-time lung fluid measurements, potentially enabling earlier intervention and preventing hospital readmissions. While the company is still in a pre-commercial stage, its technology has the potential to disrupt the heart failure monitoring market, which is dominated by implantable devices and less reliable remote monitoring tools. Success will depend on obtaining regulatory clearance, demonstrating clinical utility, and securing commercialization partnerships.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for CardioConnect platform60% success
• Q2 2027Publication of pivotal clinical study results55% success
• Q4 2026Strategic partnership with a major healthcare system or device manufacturer40% success